Tango Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Tango Therapeutics, Inc. (TNGX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-130.30-101.74-108.18-58.24-51.97
Depreciation & Amortization2.502.421.610.900.72
Stock Based Compensation28.9019.0814.237.831.76
Change in Working Capital-31.75-37.97-18.49-11.35118.67
Change in Accounts Receivable0.002.000.000.00-2.00
Change in Accounts Payable-1.18-1.711.101.231.17
Change in Other Working Capital-30.56-6.73-2.731.320.42
Other Operating Activities-0.853.631.751.320.89
Net Cash from Operating Activities-131.50-117.98-109.08-59.5370.07
Investing Activities
Capital Expenditures-0.75-1.53-7.69-1.84-1.11
Purchases of Investments-240.8942.9534.09-372.36-144.32
Sales/Maturities of Investments327.77353.53242.60190.760.00
Other Investing Activities0.000.000.000.00-0.04
Net Cash from Investing Activities86.1341.4326.40-183.43-145.47
Financing Activities
Common Stock Issued41.7282.651.621.060.04
Other Financing Activities5.94-0.24-0.01-15.840.00
Net Cash from Financing Activities47.6682.411.62357.3380.88
Summary
Net Change in Cash2.295.85-81.07114.365.49
Cash at Beginning of Period69.8163.96145.0230.660.00
Cash at End of Period72.1069.8163.96145.020.00
Free Cash Flow-132.26-119.51-116.77-61.3668.97